{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:31:39Z","timestamp":1761532299405,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.brachy.2022.12.002","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T07:27:12Z","timestamp":1673076432000},"page":"304-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of salvage high dose-rate brachytherapy with or without pelvic external beam radiotherapy in patients with palpable local recurrence of prostate cancer after radical prostatectomy"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-0900","authenticated-orcid":false,"given":"Lisa","family":"Ni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Phuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali R.","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony C.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2972-657X","authenticated-orcid":false,"given":"Osama","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3113-121X","authenticated-orcid":false,"given":"I-Chow","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2022.12.002_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"Cancer J Clin"},{"issue":"2","key":"10.1016\/j.brachy.2022.12.002_bib0002","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.juro.2013.05.032","article-title":"Adjuvant and salvage radiotherapy after prostatectomy: AUA\/ASTRO guideline","volume":"190","author":"Thompson","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0003","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.brachy.2022.12.002_bib0004","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0022-5347(17)41037-8","article-title":"The value of serum prostate specific antigen determinations before and after radical prostatectomy","volume":"141","author":"Lange","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0005","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0022-5347(05)67817-2","article-title":"Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer","volume":"163","author":"Pisansky","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0006","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000000295","article-title":"Adjuvant and salvage radiotherapy after prostatectomy: ASTRO\/AUA guideline amendment 2018-2019","volume":"202","author":"Pisansky","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0007","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.brachy.2022.12.002_bib0008","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.radonc.2020.03.033","article-title":"Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer","volume":"147","author":"Parzen","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0009","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2018.12.003","article-title":"Pelvic complications after prostate cancer radiation therapy and their management: An International Collaborative Narrative Review","volume":"75","author":"Matta","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0010","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/01.ju.0000113299.34404.22","article-title":"High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds","volume":"171","author":"Grills","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0011","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2015.07.2290","article-title":"High-dose-rate monotherapy for localized prostate cancer: 10-year results","volume":"94","author":"Hauswald","year":"2016","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.brachy.2022.12.002_bib0012","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiother Oncol"},{"journal-title":"Journal of Urology. Accessed","article-title":"AUA\/ASTRO\/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options","year":"2022","key":"10.1016\/j.brachy.2022.12.002_bib0013"},{"key":"10.1016\/j.brachy.2022.12.002_bib0014","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.juro.2018.01.002","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO Guideline. Part II: recommended approaches and details of specific care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0016","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2019.11.415","article-title":"Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial","volume":"106","author":"Joseph","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.002_bib0017","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ijrobp.2020.11.008","article-title":"Long-term results of NRG oncology\/RTOG 0321: a phase II trial of combined high dose rate brachytherapy and external beam radiation therapy for adenocarcinoma of the prostate","volume":"110","author":"Hsu","year":"2021","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.brachy.2022.12.002_bib0018","doi-asserted-by":"crossref","first-page":"477","DOI":"10.5114\/jcb.2016.64441","article-title":"Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy","volume":"8","author":"Buchser","year":"2016","journal-title":"J Contemp Brachyther"},{"key":"10.1016\/j.brachy.2022.12.002_bib0019","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.ijrobp.2003.09.082","article-title":"Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy","volume":"58","author":"Macdonald","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.002_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.brachy.2013.09.008","article-title":"High-dose-rate brachytherapy with or without intensity modulated radiation therapy as salvage treatment for an isolated, gross local recurrence of prostate cancer post-prostatectomy","volume":"13","author":"Strom","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.002_bib0021","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","volume":"177","author":"Cookson","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0022","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.brachy.2015.06.004","article-title":"Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer","volume":"14","author":"Raleigh","year":"2015","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.002_bib0023","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.brachy.2019.03.002","article-title":"Single-fraction brachytherapy as monotherapy for early-stage prostate cancer: The UCSF experience","volume":"18","author":"Xu","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.002_bib0024","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0025","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"0","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.brachy.2022.12.002_bib0026","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0027","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.brachy.2022.12.002_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.669261","article-title":"Salvage radiotherapy for macroscopic local recurrence following radical prostatectomy","volume":"11","author":"Zaine","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.715020","article-title":"Feasibility and outcome of PSMA-PET-based dose-escalated salvage radiotherapy versus conventional salvage radiotherapy for patients with recurrent prostate cancer","volume":"11","author":"Vogel","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.brachy.2004.12.004","article-title":"Feasibility and preliminary outcome of salvage combined HDR brachytherapy and external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy","volume":"4","author":"Niehoff","year":"2005","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.002_bib0031","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"18F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.brachy.2022.12.002_bib0032","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0033","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.urology.2018.12.055","article-title":"Location of recurrence by Gallium-68 PSMA-11 PET scan in prostate cancer patients eligible for salvage radiotherapy","volume":"129","author":"Boreta","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2022.12.002_bib0034","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","article-title":"Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy","volume":"25","author":"Stephenson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2022.12.002_bib0035","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijrobp.2011.10.069","article-title":"The timing of salvage radiotherapy after radical prostatectomy: a systematic review","volume":"84","author":"King","year":"2012","journal-title":"Int J Radiat Oncol*Biol*Phys"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472122003865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472122003865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:18:52Z","timestamp":1761531532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472122003865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1538472122003865"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2022.12.002","relation":{},"ISSN":["1538-4721"],"issn-type":[{"type":"print","value":"1538-4721"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of salvage high dose-rate brachytherapy with or without pelvic external beam radiotherapy in patients with palpable local recurrence of prostate cancer after radical prostatectomy","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2022.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}